Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic.
Journal
Joint Commission journal on quality and patient safety
ISSN: 1938-131X
Titre abrégé: Jt Comm J Qual Patient Saf
Pays: Netherlands
ID NLM: 101238023
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
27
10
2021
revised:
20
12
2021
accepted:
03
01
2022
pubmed:
9
2
2022
medline:
6
4
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
Prior to the COVID-19 pandemic, warfarin users were required to complete in-person training in order to participate in approved international normalized ratio (INR) patient self-testing (PST) programs. To minimize in-person contact during the pandemic, a federal waiver of the in-person training requirement allowed new patients to begin PST after completing virtual training. However, it was uncertain whether such patients achieved comparable levels of INR control to patients receiving in-person training. INR results for patients receiving virtual training upon PST commencement between April 1, 2020, and December 31, 2020, were compared to those of patients initiating PST with in-person training between April 1, 2019, and December 31, 2019. The primary outcome was the difference in warfarin time in therapeutic range (TTR) between the groups, with secondary outcomes including differences in the percentages of INR values within individually prescribed INR range and of critical INR values. The records of 33,683 patients were included in the analysis (13,568 in the "In-Person" sample; 20,115 in the "Virtual" sample). Patients in the Virtual sample achieved a TTR of 66.78%, compared to the In-Person sample (64.19%; absolute difference 2.59; 95% confidence interval [CI] = 2.50-2.68, p < 0.001). The TTR values were also statistically significantly higher in all subgroups evaluated across categories of patient age, gender, geography, and indication. Similarly favorable results were achieved for INR values in range and critical values. Virtual education for PST for warfarin therapy is effective and should continue to be an option for patients and providers throughout the pandemic, and possibly beyond.
Sections du résumé
BACKGROUND
Prior to the COVID-19 pandemic, warfarin users were required to complete in-person training in order to participate in approved international normalized ratio (INR) patient self-testing (PST) programs. To minimize in-person contact during the pandemic, a federal waiver of the in-person training requirement allowed new patients to begin PST after completing virtual training. However, it was uncertain whether such patients achieved comparable levels of INR control to patients receiving in-person training.
METHODS
INR results for patients receiving virtual training upon PST commencement between April 1, 2020, and December 31, 2020, were compared to those of patients initiating PST with in-person training between April 1, 2019, and December 31, 2019. The primary outcome was the difference in warfarin time in therapeutic range (TTR) between the groups, with secondary outcomes including differences in the percentages of INR values within individually prescribed INR range and of critical INR values.
RESULTS
The records of 33,683 patients were included in the analysis (13,568 in the "In-Person" sample; 20,115 in the "Virtual" sample). Patients in the Virtual sample achieved a TTR of 66.78%, compared to the In-Person sample (64.19%; absolute difference 2.59; 95% confidence interval [CI] = 2.50-2.68, p < 0.001). The TTR values were also statistically significantly higher in all subgroups evaluated across categories of patient age, gender, geography, and indication. Similarly favorable results were achieved for INR values in range and critical values.
CONCLUSION
Virtual education for PST for warfarin therapy is effective and should continue to be an option for patients and providers throughout the pandemic, and possibly beyond.
Identifiants
pubmed: 35131178
pii: S1553-7250(22)00002-2
doi: 10.1016/j.jcjq.2022.01.001
pmc: PMC8763408
pii:
doi:
Substances chimiques
Anticoagulants
0
Warfarin
5Q7ZVV76EI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-221Informations de copyright
Published by Elsevier Inc.
Références
Front Cardiovasc Med. 2021 Mar 29;8:648265
pubmed: 33855052
Lancet. 2006 Feb 4;367(9508):404-11
pubmed: 16458764
J Pharm Pract. 2018 Apr;31(2):150-156
pubmed: 28441899
J Surg Res. 2006 Dec;136(2):232-7
pubmed: 16999978
Thromb Haemost. 2019 Oct;119(10):1632-1641
pubmed: 31370074
Circulation. 2008 Nov 11;118(20):2029-37
pubmed: 18955670
J Thromb Haemost. 2004 Apr;2(4):584-91
pubmed: 15102012
J Thromb Haemost. 2008 Mar;6(3):451-6
pubmed: 18088347
Br J Haematol. 2005 Feb;128(4):513-9
pubmed: 15686461
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047
Am J Cardiovasc Drugs. 2020 Aug;20(4):301-309
pubmed: 32458370
Thromb Res. 2021 Sep;205:81-83
pubmed: 34265606
Egypt Heart J. 2020 Oct 16;72(1):70
pubmed: 33064222
Ann Pharmacother. 2008 Jul;42(7):979-88
pubmed: 18559954
JAMA Health Forum. 2020 Jul 1;1(7):e200900
pubmed: 36218702
Am J Manag Care. 2014 Mar;20(3):202-9
pubmed: 24884750